Pfizer Sells Capsugel Pill Unit to KKR for $2.4 Billion

Pfizer Inc., the world’s biggest drugmaker, agreed to sell its Capsugel manufacturing unit to KKR & Co. for $2.38 billion in an effort to focus on its higher-profit business developing new medicines.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.